Prabhudas Lilladher has maintained its hold rating on Emami while revising the target price downward to ₹443 from the earlier ₹469. According to the research report dated August 04, 2026, the brokerage has cut FY27/28 EPS estimates by 9.4%/7.5% respectively, assuming a normalized tax rate of 25-26%. The stock is valued at 20x June 2028 EPS.
The company's Q1 FY27 results showed higher topline growth but faced margin pressure due to sharp input cost increases and rising share of lower-margin D2C business. As reported by Prabhudas Lilladher, hair and scalp care segment performed well with 11% growth, while skincare and OTC segments showed tepid growth. The IBD sales declined by 12% while D2C sales grew 61% YoY.
According to latest financial data, Emami's Q1 FY27 earnings per share came in at ₹3.30, which was 12.23% below the estimated ₹3.76, while revenue reached ₹9.25 billion compared to the estimated ₹9.66 billion. The company's net income for the quarter was ₹1.43 billion, showing 0.00% change from the previous quarter's ₹3.19 billion. EBITDA stands at ₹9.64 billion with a current EBITDA margin of 25.91%.
Currently trading at ₹402.35, Emami's stock has shown 2.69% growth in the past 24 hours but declined 3.5% in the previous week and 6.72% for the month. The stock has experienced a 34.04% decline over the past year. According to TradingView analysis, 24 analysts have price forecasts ranging from ₹404 to ₹640, with the company having a market capitalization of ₹172.27 billion and 5,450 employees as of August 5, 2026. Technical analysis shows mixed signals with sell ratings for both 1-week and 1-month periods.
